Molecular

Translocation Assays

– BCL1/JH Translocation Assays Developed by the BIOMED-2 Group, these assays identify BCL1/JH t(11;14) translocations using a single master mix that targets BCL1 MTC locus of chromosome 11 and the JH locus of chromosome 14.
– BCL2/JH t(14;18) Translocation Assays Identifies BCL2/JH t(14;18) translocations using four master mixes that target the Mbr and mcr loci on chromosome 18 and the JH locus of chromosome 14. This assay can be performed as a nested or non-nested assay.
– BCL2/JH Translocation Assays Developed by the BIOMED-2 Group, these assays identify BCL2/JH t(14;18) translocations using three master mixes that target the Mbr, 3′ Mbr, and mcr loci on chromosome 18, and the JH locus of chromosome 14.
– BCR/ABL t(9;22) Translocation Assays Identifies BCR/ABL t(9;22) translocations using seven master mixes that target the p190 e1a2, p210 b3a2, and p210 b2a2 translocation products. This assay is a nested assay.
– PML/RARa t(15;17) Translocation Assays Identifies PML/RARa t(15;17) translocations using three master mixes that target both the short and long form translocation products. This assay is a nested assay.
– FLT3 – Mutations on the FLT3 Gene are the most common in subjects with acute Myeloid Leukemia (AML). These mutations are characterized by an aggressive phenotype and a high prevalence of relapse, occurring in approximately 30% of subjects. The FLT3 gene encodes a FMS related tyrosine kinase 3 receptor that is normally expressed in many cell types including hematologic stem cells. Invivoscribe offers a standardized FLT3 mutation test that detects both FLT3 ITD and FLT3 TKD mutations.
– FLT3 brochure and Technical Brief also attached.

For more information, please visit the IVS website.